GLW Medical is a medical technology company focused on advancing orthopedic extremity and trauma surgery. We combine traditional and minimally invasive techniques with advanced manufacturing, including 3D printing and our proprietary Ortholucent Technology Platform, to create implants and instruments that enhance surgical efficiency and support faster patient recovery.
WE DEVELOP.
We engineer breakthrough solutions, leveraging advanced manufacturing to design, develop, and commercialize innovative orthopedic implants and instruments that set new standards in performance and reliability.
WE PARTNER.
We collaborate with surgeons through integrated R&D partnerships, transforming ideas into market-ready solutions and driving procedural innovation.
WE INNOVATE.
We own a growing portfolio of issued patents and pending applications covering hybrid materials and cost-effective manufacturing methods—pioneering the next generation of orthopedic solutions.
2015
2017
2021
2022
2023
2024
GLW, Inc. Founded
Research &
Development
CREED FDA 510(k) Approval
FUSIONFRAME FDA 510(k) Approval
ISO13485:2016 Certified
Commercialization
Early Product Release
ARTEMIS FDA 510(k) Approval
APOLLO FDA 510(k) Approval
Innov8ortho Partnership
Sales Distribution
CREED HAMMERTHREAD
Product Release
MDSAP Certified
Full Market Product Releases
Global Expansion
MEDICAL DEVICE DEVELOPMENT
World-Class Engineering
All startups companies have two enemies, cash burn and time. GLW has assembled a Research & Development (“R&D”) team which can, and has, “hit the ground running” resulting in projects moving faster than what is usual and customary in our industry. We look for ways to maximize speed to market without sacrificing quality or core competency. Our R&D team has the ability to evaluate a product strategy, frame up ideas and prototype concepts (working closely with design surgeons and internal engineering staff to gather feedback and design input), and then implements product solutions quickly and effectively.
Quality Management System
GLW believes that committing assets to the implementation and maintenance of a robust Quality Management System (“QMS”) is the way to “future-proof” our investment in a startup. We are MDSAP and ISO13485:2016 certified and conforming with FDA 21 CFR part 820 Quality System Regulations with particular focus on: 1) Design Control; 2) Risk Management; 3) Document Control & Records Management; and 4) Supplier Management. Our QMS is overseen by quality, regulatory, and legal professionals with decades of combined experience in medical devices.
Surgeon Centric Design Process
Design surgeons are an integral part of our design and development process. We assemble surgeon design teams specifically to each product and collect design and other product input from them. We identify the risks and concerns that surgeon design teams identify and then work systematically to mitigate those risks and address those concerns one after the next. Design surgeons are invaluable to our business strategy as they are the window into our future customer base. This approach, implementing design surgeon know-how from the start of the development process, is one of the key factors that makes investing in medical devices exciting. Engaging physicians throughout all phases of development, from design concept through prototype development and feasibility, and eventually marketing and educational strategies, allows a GLW startup to provide a laser-focused approach to streamlining the entire process of bringing a product to market. This has vastly improved the speed of development and has shortened the turnaround time of implant design, generation, and manufacture.
From Intellectual Property (“IP”) to Investable Intellectual Portfolio
We are passionate about our IP strategizing. Does the company have the freedom to operate in that field? What licenses might one need from third parties? We don’t waste money filing patent applications that are not essential to our product portfolio strategy. We restrict applications to those inventions that are worthwhile and those territories where there will have determined there will be a market or where we will be manufacturing. At the same time, we do not have tunnel-vision with respect to our IP strategy; we continuously consider and evaluate territories and markets where we might one day want to operate and do not limit ourselves only to those we are in today.
Scalable Manufacturing
A successful product design process must proactively consider and account for what is needed for the end goal of manufacturing. We create functional prototypes using design that contemplates at every juncture the relevant manufacturability practices. Investing in scalable manufacturing processes while reducing implant cost is at the core of GLW business model. Our innovative manufacturing processes do not restrict us in ways that traditional manufacturing currently does. This has given us significant degrees of freedom to allow for innovative designs that have never before been seen in the orthopedic market.
The Value Of Our Network
Engagement with end users is also very important to our product development process. Our team has an extensive collective network in the orthopedic and wider medical device marketplace including physicians, operators in manufacturing companies, and operators in distribution companies. Through our deep network, we can build a vast body of knowledge in a short period of time. Members of GLW have worked diligently to build their relationships within the industry over the course of decades. These relationships make it possible to address and resolve very complex problems simply by making a quick phone call and having an informal conversation with some of the best minds in the industry.
CREATING OPPORTUNITIES
Collaborate To Create
We are proud of our work with HCPs and have policies to ensure our interactions with HCPs are principled and appropriate. We invest in surgeon entrepreneurs with great ideas and provide them with direction and resources required to start bringing their product visions to life.
Inner Entrepreneur
Because of our unique background and expertise, we are able to develop, and commercialize products with a great amount of confidence and proven talent. We relentlessly support ambitions of all who dare to take on intelligent risk. We refuse to be bound by typical design and manufacturing constraints. Where solutions are not obvious, we maintain the freedom to explore until we find them.
Management
Our Leadership Team
Vadim Gurevich
Co-Founder, President & CEO
Axel Cremer
Co-Founder, Chief Technology Officer
Anthony Piombino
Chief Financial Officer
Garret Mauldin
Sr. Director, R&D United States
Arundhati Radhakrishnan
Director of Quality & Regulatory Affairs
Vadim Gurevich
Co-Founder, President & CEO
Mr. Gurevich is a seasoned C-suite executive and entrepreneurial leader with more than 20 years of experience driving innovation and growth in the medical device industry. His expertise spans orthopedic foot & ankle, trauma, urogynaecology, general surgery, and neurosurgery, with deep expertise in orthopedic implant development. Vadim brings extensive experience in M&A, licensing, and post-acquisition integration.
Most recently, Vadim served as President & CEO of Novastep, Inc., where he transformed the company into a market leader in percutaneous bunion correction and successfully guided its acquisition by Enovis Corp. His career includes senior leadership roles at Stryker Orthopaedics, Integra LifeSciences, Synovis Surgical (Baxter BioSurgery), and Gyrus Medical (Olympus). Over the years, Vadim has launched disruptive medical technologies, advanced orthopedic implants, and executed strategic transactions that shaped the industry.
Product development, surgeon collaboration, and procedural innovation are central to Vadim’s philosophy, ensuring solutions deliver meaningful clinical impact. As Co-Founder of GLW Medical, Vadim leverages his deep experience, strong trans-Atlantic medtech partnerships, and a sharp focus on U.S. commercialization strategies to position GLW Medical for success in the global medical technology business.
Axel Cremer
Co-Founder, Chief Technology Officer
Mr. Cremer brings over 25 years of product development, design and management experience in the orthopedics industry. As senior manager and technical leader at Stryker Orthopaedics, he has led the development of T2 IM nails, Hoffmann 3 external fixation, Pelvis Pro and Axsos 3 plating product platforms.
Axel is one of the industry’s leading experts in titanium plating technologies, having spearheaded the global development for the Axsos 3 plating system at Stryker. He also directed Stryker’s strategic relationship with the US Department of Defense and led the engineering efforts to design the Hoffmann external fixation system for the military in order to be prepared to treat casualties in an austere environment.
Axel holds over 100 patents and was the primary trauma representative for all Stryker US based interdivisional projects. He was involved in multiple business development evaluations for Stryker and acted as the point of contact for trauma surgeons submitting product development ideas to the company.
Dynamic leadership and a commitment to advancing orthopedic solutions define Axel’s approach, driving medical technologies that improve patient outcomes. As Co-Founder and Chief Technology Officer of GLW Medical, Axel brings unmatched technical expertise and strategic vision to shape the company’s innovation roadmap.
Anthony Piombino
Chief Financial Officer
Mr. Piombino is a seasoned financial executive with more than 20 years of experience serving as CFO for private equity-backed and privately held companies. He specializes in financial strategy and recapitalization, with a proven ability to align financial infrastructure and reporting with long-term business objectives.
Anthony is passionate about helping start-ups establish structure and implement robust financial controls, ensuring a strong foundation for growth and scalability.
Before joining GLW Medical, Anthony served as Chief Financial Officer at Novastep, Inc., where he played a pivotal role in the company’s successful acquisition by Enovis Corp.
Garret Mauldin
Sr. Director, R&D United States
Mr. Mauldin brings over 20 years of experience in the orthopedics industry and a proven track record of driving innovation and growth. He has played a pivotal role in two successful start-ups: Inbone Technologies, acquired at a 7X return on investment, and SI-Bone, which achieved a successful IPO.
Recognized as one of the leading experts in total ankle replacement, Garret developed the groundbreaking Inbone ankle system and contributed to advancements in the Salto Talaris and Cadence ankle systems.
At GLW Medical, Garret has created transformative 3D-printed titanium plating technologies and spearheaded the company’s pivot into minimally invasive systems (MIS)—setting new standards for surgical innovation.
His expertise extends beyond orthopedics, with experience in automotive, fiber optics, electronics, automation/robotics, manufacturing, and military defense—industries where he has consistently delivered innovative, market-leading products.
Garret holds both a BSME and MSME from Texas A&M University and is the inventor of more than 20 patents across multiple industries.
Arundhati Radhakrishnan
Director of Quality & Regulatory Affairs
Mrs. Arundhati (Dhati) Radhakrishnan is an accomplished leader in the medical device industry with extensive experience in Regulatory Affairs and Quality Assurance. She has been instrumental in building and sustaining world-class Quality Management Systems (QMS) that enable innovation while ensuring full compliance with global standards. At GLW Medical, Dhati spearheaded the development of a comprehensive QMS, leading the organization to achieve ISO 13485 and MDSAP certifications and consistently meet every regulatory and quality requirement.
Her leadership extends beyond compliance—Dhati has defined and executed regulatory strategies, successfully managing FDA 510(k) submissions and navigating complex international regulations. She combines technical expertise with strategic vision, ensuring that product development aligns seamlessly with regulatory pathways.
Dhati holds a M.S. in Biomedical Engineering from Delft University of Technology (TU Delft), Netherlands, and a B.E. from B.M.S. College of Engineering (BMSCE), Bangalore, India.
press releases
GLW Medical to Expand MIS Solutions and Introduce CREED Edge
Englewood Cliffs, NJ – GLW, Inc. (“GLW Medical” or the “Company”), a medical technology company focused on advancing orthopedic extremity and trauma surgery, today announced its upcoming product showcase at the 2025 American Orthopaedic Foot & Ankle Society (AOFAS) Annual Meeting, taking place September 10–13 in Savannah, Georgia. GLW Medical will debut the CREED Edge Cannulated … Continued
GLW Medical Announces Full Market Release of the Apollo Ankle Fracture Plating System
Englewood Cliffs, NJ., — GLW, Inc. (“GLW Medical” or the “Company”) with a focus on the foot and ankle orthopedic market is excited to announce the full market release of its Apollo Ankle Fracture (AFX) Plating System. The Company has commercialized its patented, first of its kind, additive manufactured titanium shell polyetheretherketone filled (TI-PEEK) plates … Continued
GLW Announces Additional FDA 510(K) Clearance for the Artemis Proximal Femoral Nail System
NEW LONG NAIL TO STRENGTHEN THE ARTEMIS SYSTEM AND STREAMLINE WORKFLOWS ENGLEWOOD CLIFFS, NJ, USA, October 31, 2022 / – GLW Trauma, a GLW Medical Innovation (GLW) company focused on a paradigm shift in the surgical treatment of trochanteric hip fractures, announced today an additional U.S. Food and Drug Administration (FDA) 510(k) clearance of the … Continued
GLW Receives FDA 510(k) Clearance for Apollo Ankle Fracture Plating System
Englewood Cliffs, NJ., — GLW Foot & Ankle (Carbon22), a GLW Medical Innovation company (GLW) with a focus on the foot and ankle orthopedic market, today announced it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) to market its upcoming Apollo Ankle Fracture (AFX) Plating System, a novel portfolio of see-through, … Continued
Solvay and GLW partner on Creed™ Cannulated Compression Screws for orthopedics
Alpharetta, Ga., — Solvay’s Zeniva® polyetheretherketone (PEEK) resin was chosen by GLW Foot & Ankle (Carbon22), a GLW Medical Innovation company for its new Creed™ Cannulated Screw System for foot and ankle surgery. This advanced new screw system recently received 510(k) clearance from the U.S. Food and Drug Administration (FDA). To create the new system’s ortholucent, plastic-metal hybrid … Continued
GLW Announces FDA 510(K) Clearance for the Artemis Proximal Femoral Nail System
A FOURTH-GENERATION HIP FRACTURE NAIL MANUFACTURED USING A REVOLUTIONARY PROCESS ENGLEWOOD CLIFFS, NJ, USA, February 22, 2021 / – GLW Trauma, a GLW Medical Innovation (GLW) company announced today that it has received 510(k) clearance from the U.S. Food and Drug Administration for its Artemis Proximal Femoral Nail (PFN) System, a hip fracture nail. The … Continued
